Subtitle: Market Intelligence, Clinical Progress, and High-Purity Reagents for Autoimmune and B-Cell Malignancy Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for TNFRSF13C (BAFF-R) drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | TNFRSF13C ECD-Fc / Mutant Protein High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. |
View TNFRSF13C Products |
| Gene Delivery | TNFRSF13C Promise-ORF / Lentivirus Full-length ORF for stable cell lines. |
View TNFRSF13C Products |
| Benchmark Ab | Anti-TNFRSF13C (Sequence of Ianalumab) Recombinant positive control. |
View TNFRSF13C Products |
| Validator | TNFRSF13C siRNA Set For knockdown verification. |
View TNFRSF13C Products |
| Related Target A | TNFSF13B (BAFF) Primary natural ligand for competitive binding assays. |
View TNFSF13B Products |
| Related Target B | TNFRSF17 (BCMA) Homolog receptor for crucial selectivity counter-screening. |
View TNFRSF17 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Receptor Subfamily Cross-reactivity | Strictly verified BCMA and TACI homolog proteins available with >95% purity for off-target screening |
| Conformational Epitope Preservation | HEK293 Expressed (Native Glycosylation) ECD proteins to maintain native folding |
| Lack of Reliable Controls | Clinical Benchmark Antibodies (Biosimilars) included with Sequence Verified precision |
| False Positives in Cell Assays | Valid Lentivirus delivery for stable cell construction and siRNA for specificity knockdown checks |
Live TNFRSF13C R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for TNFRSF13C therapeutics is intensifying, with major players shifting focus from traditional mAbs to ADCC-enhanced antibodies and CAR-T cell therapies. As first-generation therapies targeting the BAFF/BAFF-R axis reach advanced clinical stages for autoimmune diseases like SLE and Sjogren's syndrome, the next wave of R&D is targeting refractory B-cell malignancies through engineered cellular therapies and bispecific platforms.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Naked mAb (ADCC) | Novartis (Ianalumab) | Sjogren's, SLE, CLL | High-Affinity Binding (Need High-Purity HEK293 ECD-Fc) |
| CAR-T | City of Hope, Various Biotech | Refractory B-Cell Lymphoma | Target Cell Validation (Need Lentivirus for Stable Cell Lines) |
| Bispecifics | Emerging Innovators | Autoimmune Diseases | Heterodimer Validation (Need Cross-reactive Abs & Ligands) |